TrialsgrambetaRCTs are beautiful

SUSTAIN-6

2016

Trial to Evaluate CV and Other Long-term Outcomes with Semaglutide

In 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.

Result

Efficacy: 3-point MACEHR 0.74 · P = 0.02

Safety: Retinopathy complicationsHR 1.76 · P = 0.02

Below 1 favours subcutaneous semaglutide 0.5 or 1.0 mg weekly, above 1 favours placebo.

Event rates Subcutaneous semaglutide 0.5 or 1.0 mg weekly 6.6% vs placebo 8.9% (3-point MACE)

Also reported: Non-fatal stroke −39 %.

Original publication
Subtopic
CV outcome trial
Design
Double-blind RCT, median 2.1 yr
Relevance
Important: one of several pillars.
Source
Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.doi 10.1056/NEJMoa1607141

Discussion & critique

Confirmed the GLP-1 RA class effect on MACE; the retinopathy signal remains debated and probably reflects rapid glycaemic improvement.

Discussed in podcasts